IBDEI1XQ ; ; 04-FEB-2020
;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
Q:'DIFQR(358.3) F I=1:2 S X=$T(Q+I) Q:X="" S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E S @X=Y
Q Q
;;^UTILITY(U,$J,358.3,30907,1,3,0)
;;=3^Nephrotic syndrome w/ diffuse membranous glomerulonephritis
;;^UTILITY(U,$J,358.3,30907,1,4,0)
;;=4^N04.2
;;^UTILITY(U,$J,358.3,30907,2)
;;=^5015533
;;^UTILITY(U,$J,358.3,30908,0)
;;=N04.3^^123^1597^56
;;^UTILITY(U,$J,358.3,30908,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,30908,1,3,0)
;;=3^Nephrotic syndrome w/ diffuse mesangial prolif glomrlneph
;;^UTILITY(U,$J,358.3,30908,1,4,0)
;;=4^N04.3
;;^UTILITY(U,$J,358.3,30908,2)
;;=^5015534
;;^UTILITY(U,$J,358.3,30909,0)
;;=N04.4^^123^1597^54
;;^UTILITY(U,$J,358.3,30909,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,30909,1,3,0)
;;=3^Nephrotic syndrome w/ diffuse endocaplry prolif glomrlneph
;;^UTILITY(U,$J,358.3,30909,1,4,0)
;;=4^N04.4
;;^UTILITY(U,$J,358.3,30909,2)
;;=^5015535
;;^UTILITY(U,$J,358.3,30910,0)
;;=N04.5^^123^1597^57
;;^UTILITY(U,$J,358.3,30910,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,30910,1,3,0)
;;=3^Nephrotic syndrome w/ diffuse mesangiocapillary glomrlneph
;;^UTILITY(U,$J,358.3,30910,1,4,0)
;;=4^N04.5
;;^UTILITY(U,$J,358.3,30910,2)
;;=^5015536
;;^UTILITY(U,$J,358.3,30911,0)
;;=N04.6^^123^1597^52
;;^UTILITY(U,$J,358.3,30911,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,30911,1,3,0)
;;=3^Nephrotic syndrome w/ dense deposit disease
;;^UTILITY(U,$J,358.3,30911,1,4,0)
;;=4^N04.6
;;^UTILITY(U,$J,358.3,30911,2)
;;=^5015537
;;^UTILITY(U,$J,358.3,30912,0)
;;=N04.7^^123^1597^53
;;^UTILITY(U,$J,358.3,30912,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,30912,1,3,0)
;;=3^Nephrotic syndrome w/ diffuse crescentic glomerulonephritis
;;^UTILITY(U,$J,358.3,30912,1,4,0)
;;=4^N04.7
;;^UTILITY(U,$J,358.3,30912,2)
;;=^5015538
;;^UTILITY(U,$J,358.3,30913,0)
;;=N04.8^^123^1597^60
;;^UTILITY(U,$J,358.3,30913,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,30913,1,3,0)
;;=3^Nephrotic syndrome w/ other morphologic changes
;;^UTILITY(U,$J,358.3,30913,1,4,0)
;;=4^N04.8
;;^UTILITY(U,$J,358.3,30913,2)
;;=^5015539
;;^UTILITY(U,$J,358.3,30914,0)
;;=N04.9^^123^1597^61
;;^UTILITY(U,$J,358.3,30914,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,30914,1,3,0)
;;=3^Nephrotic syndrome w/ unspecified morphologic changes
;;^UTILITY(U,$J,358.3,30914,1,4,0)
;;=4^N04.9
;;^UTILITY(U,$J,358.3,30914,2)
;;=^5015540
;;^UTILITY(U,$J,358.3,30915,0)
;;=N05.0^^123^1597^49
;;^UTILITY(U,$J,358.3,30915,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,30915,1,3,0)
;;=3^Nephritic syndrome unspec w/ minor glomerular abnormality
;;^UTILITY(U,$J,358.3,30915,1,4,0)
;;=4^N05.0
;;^UTILITY(U,$J,358.3,30915,2)
;;=^5015541
;;^UTILITY(U,$J,358.3,30916,0)
;;=N05.1^^123^1597^48
;;^UTILITY(U,$J,358.3,30916,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,30916,1,3,0)
;;=3^Nephritic syndrome unspec w/ focal & segmental glomerular lesions
;;^UTILITY(U,$J,358.3,30916,1,4,0)
;;=4^N05.1
;;^UTILITY(U,$J,358.3,30916,2)
;;=^5015542
;;^UTILITY(U,$J,358.3,30917,0)
;;=N05.2^^123^1597^45
;;^UTILITY(U,$J,358.3,30917,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,30917,1,3,0)
;;=3^Nephritic syndrome unspec w/ diffuse membranous glomrlneph
;;^UTILITY(U,$J,358.3,30917,1,4,0)
;;=4^N05.2
;;^UTILITY(U,$J,358.3,30917,2)
;;=^5015543
;;^UTILITY(U,$J,358.3,30918,0)
;;=N05.3^^123^1597^46
;;^UTILITY(U,$J,358.3,30918,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,30918,1,3,0)
;;=3^Nephritic syndrome unspec w/ diffuse mesangial prolif glomrlneph
--- Routine Detail --- with STRUCTURED ROUTINE LISTING ---[H[J[2J[HIBDEI1XQ 3762 printed Apr 09, 2024@22:00:59 Page 2
IBDEI1XQ ; ; 04-FEB-2020
+1 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
+2 if 'DIFQR(358.3)
QUIT
FOR I=1:2
SET X=$TEXT(Q+I)
if X=""
QUIT
SET Y=$EXTRACT($TEXT(Q+I+1),4,999)
SET X=$EXTRACT(X,4,999)
if $ASCII(Y)=126
SET I=I+1
SET Y=$EXTRACT(Y,2,999)_$EXTRACT($TEXT(Q+I+1),5,999)
if $ASCII(Y)=61
SET Y=$EXTRACT(Y,2,999)
XECUTE NO
IF '$TEST
SET @X=Y
Q QUIT
+1 ;;^UTILITY(U,$J,358.3,30907,1,3,0)
+2 ;;=3^Nephrotic syndrome w/ diffuse membranous glomerulonephritis
+3 ;;^UTILITY(U,$J,358.3,30907,1,4,0)
+4 ;;=4^N04.2
+5 ;;^UTILITY(U,$J,358.3,30907,2)
+6 ;;=^5015533
+7 ;;^UTILITY(U,$J,358.3,30908,0)
+8 ;;=N04.3^^123^1597^56
+9 ;;^UTILITY(U,$J,358.3,30908,1,0)
+10 ;;=^358.31IA^4^2
+11 ;;^UTILITY(U,$J,358.3,30908,1,3,0)
+12 ;;=3^Nephrotic syndrome w/ diffuse mesangial prolif glomrlneph
+13 ;;^UTILITY(U,$J,358.3,30908,1,4,0)
+14 ;;=4^N04.3
+15 ;;^UTILITY(U,$J,358.3,30908,2)
+16 ;;=^5015534
+17 ;;^UTILITY(U,$J,358.3,30909,0)
+18 ;;=N04.4^^123^1597^54
+19 ;;^UTILITY(U,$J,358.3,30909,1,0)
+20 ;;=^358.31IA^4^2
+21 ;;^UTILITY(U,$J,358.3,30909,1,3,0)
+22 ;;=3^Nephrotic syndrome w/ diffuse endocaplry prolif glomrlneph
+23 ;;^UTILITY(U,$J,358.3,30909,1,4,0)
+24 ;;=4^N04.4
+25 ;;^UTILITY(U,$J,358.3,30909,2)
+26 ;;=^5015535
+27 ;;^UTILITY(U,$J,358.3,30910,0)
+28 ;;=N04.5^^123^1597^57
+29 ;;^UTILITY(U,$J,358.3,30910,1,0)
+30 ;;=^358.31IA^4^2
+31 ;;^UTILITY(U,$J,358.3,30910,1,3,0)
+32 ;;=3^Nephrotic syndrome w/ diffuse mesangiocapillary glomrlneph
+33 ;;^UTILITY(U,$J,358.3,30910,1,4,0)
+34 ;;=4^N04.5
+35 ;;^UTILITY(U,$J,358.3,30910,2)
+36 ;;=^5015536
+37 ;;^UTILITY(U,$J,358.3,30911,0)
+38 ;;=N04.6^^123^1597^52
+39 ;;^UTILITY(U,$J,358.3,30911,1,0)
+40 ;;=^358.31IA^4^2
+41 ;;^UTILITY(U,$J,358.3,30911,1,3,0)
+42 ;;=3^Nephrotic syndrome w/ dense deposit disease
+43 ;;^UTILITY(U,$J,358.3,30911,1,4,0)
+44 ;;=4^N04.6
+45 ;;^UTILITY(U,$J,358.3,30911,2)
+46 ;;=^5015537
+47 ;;^UTILITY(U,$J,358.3,30912,0)
+48 ;;=N04.7^^123^1597^53
+49 ;;^UTILITY(U,$J,358.3,30912,1,0)
+50 ;;=^358.31IA^4^2
+51 ;;^UTILITY(U,$J,358.3,30912,1,3,0)
+52 ;;=3^Nephrotic syndrome w/ diffuse crescentic glomerulonephritis
+53 ;;^UTILITY(U,$J,358.3,30912,1,4,0)
+54 ;;=4^N04.7
+55 ;;^UTILITY(U,$J,358.3,30912,2)
+56 ;;=^5015538
+57 ;;^UTILITY(U,$J,358.3,30913,0)
+58 ;;=N04.8^^123^1597^60
+59 ;;^UTILITY(U,$J,358.3,30913,1,0)
+60 ;;=^358.31IA^4^2
+61 ;;^UTILITY(U,$J,358.3,30913,1,3,0)
+62 ;;=3^Nephrotic syndrome w/ other morphologic changes
+63 ;;^UTILITY(U,$J,358.3,30913,1,4,0)
+64 ;;=4^N04.8
+65 ;;^UTILITY(U,$J,358.3,30913,2)
+66 ;;=^5015539
+67 ;;^UTILITY(U,$J,358.3,30914,0)
+68 ;;=N04.9^^123^1597^61
+69 ;;^UTILITY(U,$J,358.3,30914,1,0)
+70 ;;=^358.31IA^4^2
+71 ;;^UTILITY(U,$J,358.3,30914,1,3,0)
+72 ;;=3^Nephrotic syndrome w/ unspecified morphologic changes
+73 ;;^UTILITY(U,$J,358.3,30914,1,4,0)
+74 ;;=4^N04.9
+75 ;;^UTILITY(U,$J,358.3,30914,2)
+76 ;;=^5015540
+77 ;;^UTILITY(U,$J,358.3,30915,0)
+78 ;;=N05.0^^123^1597^49
+79 ;;^UTILITY(U,$J,358.3,30915,1,0)
+80 ;;=^358.31IA^4^2
+81 ;;^UTILITY(U,$J,358.3,30915,1,3,0)
+82 ;;=3^Nephritic syndrome unspec w/ minor glomerular abnormality
+83 ;;^UTILITY(U,$J,358.3,30915,1,4,0)
+84 ;;=4^N05.0
+85 ;;^UTILITY(U,$J,358.3,30915,2)
+86 ;;=^5015541
+87 ;;^UTILITY(U,$J,358.3,30916,0)
+88 ;;=N05.1^^123^1597^48
+89 ;;^UTILITY(U,$J,358.3,30916,1,0)
+90 ;;=^358.31IA^4^2
+91 ;;^UTILITY(U,$J,358.3,30916,1,3,0)
+92 ;;=3^Nephritic syndrome unspec w/ focal & segmental glomerular lesions
+93 ;;^UTILITY(U,$J,358.3,30916,1,4,0)
+94 ;;=4^N05.1
+95 ;;^UTILITY(U,$J,358.3,30916,2)
+96 ;;=^5015542
+97 ;;^UTILITY(U,$J,358.3,30917,0)
+98 ;;=N05.2^^123^1597^45
+99 ;;^UTILITY(U,$J,358.3,30917,1,0)
+100 ;;=^358.31IA^4^2
+101 ;;^UTILITY(U,$J,358.3,30917,1,3,0)
+102 ;;=3^Nephritic syndrome unspec w/ diffuse membranous glomrlneph
+103 ;;^UTILITY(U,$J,358.3,30917,1,4,0)
+104 ;;=4^N05.2
+105 ;;^UTILITY(U,$J,358.3,30917,2)
+106 ;;=^5015543
+107 ;;^UTILITY(U,$J,358.3,30918,0)
+108 ;;=N05.3^^123^1597^46
+109 ;;^UTILITY(U,$J,358.3,30918,1,0)
+110 ;;=^358.31IA^4^2
+111 ;;^UTILITY(U,$J,358.3,30918,1,3,0)
+112 ;;=3^Nephritic syndrome unspec w/ diffuse mesangial prolif glomrlneph
